Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 12;18(9):1960.
doi: 10.3390/ijms18091960.

MicroRNAs in Different Histologies of Soft Tissue Sarcoma: A Comprehensive Review

Maria Anna Smolle  1 , Andreas Leithner  2 , Florian Posch  3 , Joanna Szkandera  4 , Bernadette Liegl-Atzwanger  5 , Martin Pichler  6
Affiliations
Review

MicroRNAs in Different Histologies of Soft Tissue Sarcoma: A Comprehensive Review

Maria Anna Smolle et al. Int J Mol Sci. .

Abstract

Soft tissue sarcomas (STS) constitute a rare tumour entity comprising over 50 histological subtypes. MicroRNAs (miRNAs) are short non-protein coding RNA molecules that regulate gene expression by targeting the 3'-untranslated region of messenger RNAs. They are involved in a variety of human diseases, including malignancies, such as endometrial cancer, osteosarcoma, bronchial carcinoma and breast cancer. In STS, various miRNAs are differentially expressed, thus contributing to development, progression and invasion. Therefore, the aim of the present review is to summarise current knowledge on the role of miRNAs in STS. Furthermore, the potential role of miRNAs as diagnostic, prognostic and predictive biomarkers is discussed.

Keywords: microRNAs; soft tissue sarcoma; tumourigenesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
miRNA expression in different soft tissue sarcoma (STS) subtypes.
See this image and copyright information in PMC

References

    1. Stiller C.A., Trama A., Serraino D., Rossi S., Navarro C., Chirlaque M.D., Casali P.G., Group R.W. Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. Eur. J. Cancer. 2013;49:684–695. doi: 10.1016/j.ejca.2012.09.011. - DOI - PubMed
    1. Smolle M.A., Tunn P.U., Goldenitsch E., Posch F., Szkandera J., Bergovec M., Liegl-Atzwanger B., Leithner A. The Prognostic Impact of Unplanned Excisions in a Cohort of 728 Soft Tissue Sarcoma Patients: A Multicentre Study. Ann. Surg. Oncol. 2017;24:1596–1605. doi: 10.1245/s10434-017-5776-8. - DOI - PMC - PubMed
    1. Ducimetiere F., Lurkin A., Ranchere-Vince D., Decouvelaere A.V., Peoc’h M., Istier L., Chalabreysse P., Muller C., Alberti L., Bringuier P.P., et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS ONE. 2011;6:e20294. doi: 10.1371/journal.pone.0020294. - DOI - PMC - PubMed
    1. Casali P.G., Blay J.Y., ESMO/CONTICANET/EUROBONET Consensus Panel of experts Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010;21(Suppl. 5):v198–v203. doi: 10.1093/annonc/mdq209. - DOI - PubMed
    1. Posch F., Leitner L., Bergovec M., Bezan A., Stotz M., Gerger A., Pichler M., Stoger H., Liegl-Atzwanger B., Leithner A., et al. Can Multistate Modeling of Local Recurrence, Distant Metastasis, and Death Improve the Prediction of Outcome in Patients With Soft Tissue Sarcomas? Clin. Orthop. Relat. Res. 2017;475:1427–1435. doi: 10.1007/s11999-017-5232-x. - DOI - PMC - PubMed

LinkOut - more resources